Jimmy Suryadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jimmy Suryadi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth R. Sharlow
Department of Pharmacology, University of Virginia, Charlottesville, VA, USA
1 shared publication - James C. Morris
Eukaryotic Pathogens Innovation Center, Department of Genetics and Biochemistry, Clemson University, Clemson, SC 29634, USA
1 shared publication - Jennifer E. Golden
Department of Chemistry, University of Wisconsin-Madison, 1101 University Ave, Madison, WI, 53706, United States of America; Division of Pharmaceutical Sciences, University of Wisconsin-Madison, 777 Highland Ave., Madison, WI, 537055, United States of America
1 shared publication Mark E. Drew
Departments of Microbial Infection and Immunity and Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, Ohio, USA
1 shared publicationMatthew B. Boxer
National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Rockville, Maryland, USA
1 shared publication- Matthew D. Hall
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (10) , 6023-6033
Identification of Novel Plasmodium falciparum Hexokinase Inhibitors with Antiparasitic Activity
Plasmodium falciparum , the deadliest species of malaria parasites, is dependent on glycolysis for the generation of ATP during the pathogenic red blood cell stage. Hexokinase (HK) catalyzes the first step in glycolysis, transferring the γ-phosphoryl group of ATP to glucose to yield glucose-6-phosphate. Here, we describe the validation of a high-throughput assay for screening small-molecule collections to identify inhibitors of the P. falciparum HK (PfHK). The assay, which employed an ADP-Glo reporter system in a 1,536-well-plate format, was robust with a signal-to-background ratio of 3.4 ± 1.2, a coefficient of variation of 6.8% ± 2.9%, and a Z′-factor of 0.75 ± 0.08. Using this assay, we screened 57,654 molecules from multiple small-molecule collections. Confirmed hits were resolved into four clusters on the basis of structural relatedness. Multiple singleton hits were also identified. The most potent inhibitors had 50% inhibitory concentrations as low as ∼1 μM, and several were found to have low-micromolar 50% effective concentrations against asexual intraerythrocytic-stage P. falciparum parasites. These molecules additionally demonstrated limited toxicity against a panel of mammalian cells. The identification of PfHK inhibitors with antiparasitic activity using this validated screening assay is encouraging, as it justifies additional HTS campaigns with more structurally amenable libraries for the identification of potential leads for future therapeutic development.
- 1 October 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (10) , 6023-6033
Open AccessIdentification of Novel Plasmodium falciparum Hexokinase Inhibitors with Antiparasitic Activity
Plasmodium falciparum , the deadliest species of malaria parasites, is dependent on glycolysis for the generation of ATP during the pathogenic red blood cell stage. Hexokinase (HK) catalyzes the first step in glycolysis, transferring the γ-phosphoryl group of ATP to glucose to yield glucose-6-phosphate. Here, we describe the validation of a high-throughput assay for screening small-molecule collections to identify inhibitors of the P. falciparum HK (PfHK). The assay, which employed an ADP-Glo reporter system in a 1,536-well-plate format, was robust with a signal-to-background ratio of 3.4 ± 1.2, a coefficient of variation of 6.8% ± 2.9%, and a Z′-factor of 0.75 ± 0.08. Using this assay, we screened 57,654 molecules from multiple small-molecule collections. Confirmed hits were resolved into four clusters on the basis of structural relatedness. Multiple singleton hits were also identified. The most potent inhibitors had 50% inhibitory concentrations as low as ∼1 μM, and several were found to have low-micromolar 50% effective concentrations against asexual intraerythrocytic-stage P. falciparum parasites. These molecules additionally demonstrated limited toxicity against a panel of mammalian cells. The identification of PfHK inhibitors with antiparasitic activity using this validated screening assay is encouraging, as it justifies additional HTS campaigns with more structurally amenable libraries for the identification of potential leads for future therapeutic development.